Transcript profiling in peripheral T-cell lymphoma, not otherwise specified, and diffuse large B-cell lymphoma identifies distinct tumor profile signatures

Daruka Mahadevan, Catherine S Perry, Kimiko Della Croce, Susan Miller, Benjamin George, Chris Riley, Stephen Warner, Thomas M. Grogan, Thomas P Miller

Research output: Contribution to journalArticle

69 Citations (Scopus)

Abstract

To glean biological differences and similarities of peripheral T-cell lymphoma-not otherwise specified [PTCL-NOS] to diffuse large B-cell lymphoma (DLBCL), a transcriptosome analysis was done on five PTCL-NOS and four DLBCL patients and validated by quantitative real-time reverse transcription-PCR on 10 selected genes. Normal peripheral blood T cells, peripheral blood B cells, and lymph node were used as controls. The resultant gene expression profile delineated distinct "tumor profile signatures" for PTCL-NOS and DLBCL. Several highly overexpressed genes in both PTCL-NOS and DLBCL involve the immune network, stroma, angiogenesis, and cell survival cascades that make important contributions to lymphomagenesis. Inflammatory chemokines and their receptors likely play a central role in these complex interrelated pathways: CCL2 and CXCR4 in PTCL-NOS and CCL5 and CCR1 in DLBCL. Highly overexpressed oncogenes unique to PTCL-NOS are SPI1, STK6, α-PDGFR, and SH2D1A, whereas in DLBCL they are PIM1, PIM2, LYN, BCL2A1, and RAB13. Oncogenes common to both lymphomas are MAFB, MET, NF-κB2, LCK, and LYN. Several tumor suppressors are also down-regulated (TPTE, MGC154, PTCH, ST5, and SUI1). This study illustrates the relevance of tumor-stroma immune trafficking and identified potential novel prognostic markers and targets for therapeutic intervention.

Original languageEnglish (US)
Pages (from-to)1867-1879
Number of pages13
JournalMolecular Cancer Therapeutics
Volume4
Issue number12
DOIs
StatePublished - Dec 2005

Fingerprint

Peripheral T-Cell Lymphoma
Lymphoma, Large B-Cell, Diffuse
Neoplasms
Oncogenes
Blood Cells
Chemokine Receptors
Transcriptome
Genes
Reverse Transcription
Lymphoma
Cell Survival
B-Lymphocytes
Lymph Nodes
T-Lymphocytes
Polymerase Chain Reaction

ASJC Scopus subject areas

  • Oncology
  • Drug Discovery
  • Pharmacology

Cite this

Transcript profiling in peripheral T-cell lymphoma, not otherwise specified, and diffuse large B-cell lymphoma identifies distinct tumor profile signatures. / Mahadevan, Daruka; Perry, Catherine S; Della Croce, Kimiko; Miller, Susan; George, Benjamin; Riley, Chris; Warner, Stephen; Grogan, Thomas M.; Miller, Thomas P.

In: Molecular Cancer Therapeutics, Vol. 4, No. 12, 12.2005, p. 1867-1879.

Research output: Contribution to journalArticle

Mahadevan, Daruka ; Perry, Catherine S ; Della Croce, Kimiko ; Miller, Susan ; George, Benjamin ; Riley, Chris ; Warner, Stephen ; Grogan, Thomas M. ; Miller, Thomas P. / Transcript profiling in peripheral T-cell lymphoma, not otherwise specified, and diffuse large B-cell lymphoma identifies distinct tumor profile signatures. In: Molecular Cancer Therapeutics. 2005 ; Vol. 4, No. 12. pp. 1867-1879.
@article{8b88585718cd412d9fd9dd5cda78b6cb,
title = "Transcript profiling in peripheral T-cell lymphoma, not otherwise specified, and diffuse large B-cell lymphoma identifies distinct tumor profile signatures",
abstract = "To glean biological differences and similarities of peripheral T-cell lymphoma-not otherwise specified [PTCL-NOS] to diffuse large B-cell lymphoma (DLBCL), a transcriptosome analysis was done on five PTCL-NOS and four DLBCL patients and validated by quantitative real-time reverse transcription-PCR on 10 selected genes. Normal peripheral blood T cells, peripheral blood B cells, and lymph node were used as controls. The resultant gene expression profile delineated distinct {"}tumor profile signatures{"} for PTCL-NOS and DLBCL. Several highly overexpressed genes in both PTCL-NOS and DLBCL involve the immune network, stroma, angiogenesis, and cell survival cascades that make important contributions to lymphomagenesis. Inflammatory chemokines and their receptors likely play a central role in these complex interrelated pathways: CCL2 and CXCR4 in PTCL-NOS and CCL5 and CCR1 in DLBCL. Highly overexpressed oncogenes unique to PTCL-NOS are SPI1, STK6, α-PDGFR, and SH2D1A, whereas in DLBCL they are PIM1, PIM2, LYN, BCL2A1, and RAB13. Oncogenes common to both lymphomas are MAFB, MET, NF-κB2, LCK, and LYN. Several tumor suppressors are also down-regulated (TPTE, MGC154, PTCH, ST5, and SUI1). This study illustrates the relevance of tumor-stroma immune trafficking and identified potential novel prognostic markers and targets for therapeutic intervention.",
author = "Daruka Mahadevan and Perry, {Catherine S} and {Della Croce}, Kimiko and Susan Miller and Benjamin George and Chris Riley and Stephen Warner and Grogan, {Thomas M.} and Miller, {Thomas P}",
year = "2005",
month = "12",
doi = "10.1158/1535-7163.MCT-05-0146",
language = "English (US)",
volume = "4",
pages = "1867--1879",
journal = "Molecular Cancer Therapeutics",
issn = "1535-7163",
publisher = "American Association for Cancer Research Inc.",
number = "12",

}

TY - JOUR

T1 - Transcript profiling in peripheral T-cell lymphoma, not otherwise specified, and diffuse large B-cell lymphoma identifies distinct tumor profile signatures

AU - Mahadevan, Daruka

AU - Perry, Catherine S

AU - Della Croce, Kimiko

AU - Miller, Susan

AU - George, Benjamin

AU - Riley, Chris

AU - Warner, Stephen

AU - Grogan, Thomas M.

AU - Miller, Thomas P

PY - 2005/12

Y1 - 2005/12

N2 - To glean biological differences and similarities of peripheral T-cell lymphoma-not otherwise specified [PTCL-NOS] to diffuse large B-cell lymphoma (DLBCL), a transcriptosome analysis was done on five PTCL-NOS and four DLBCL patients and validated by quantitative real-time reverse transcription-PCR on 10 selected genes. Normal peripheral blood T cells, peripheral blood B cells, and lymph node were used as controls. The resultant gene expression profile delineated distinct "tumor profile signatures" for PTCL-NOS and DLBCL. Several highly overexpressed genes in both PTCL-NOS and DLBCL involve the immune network, stroma, angiogenesis, and cell survival cascades that make important contributions to lymphomagenesis. Inflammatory chemokines and their receptors likely play a central role in these complex interrelated pathways: CCL2 and CXCR4 in PTCL-NOS and CCL5 and CCR1 in DLBCL. Highly overexpressed oncogenes unique to PTCL-NOS are SPI1, STK6, α-PDGFR, and SH2D1A, whereas in DLBCL they are PIM1, PIM2, LYN, BCL2A1, and RAB13. Oncogenes common to both lymphomas are MAFB, MET, NF-κB2, LCK, and LYN. Several tumor suppressors are also down-regulated (TPTE, MGC154, PTCH, ST5, and SUI1). This study illustrates the relevance of tumor-stroma immune trafficking and identified potential novel prognostic markers and targets for therapeutic intervention.

AB - To glean biological differences and similarities of peripheral T-cell lymphoma-not otherwise specified [PTCL-NOS] to diffuse large B-cell lymphoma (DLBCL), a transcriptosome analysis was done on five PTCL-NOS and four DLBCL patients and validated by quantitative real-time reverse transcription-PCR on 10 selected genes. Normal peripheral blood T cells, peripheral blood B cells, and lymph node were used as controls. The resultant gene expression profile delineated distinct "tumor profile signatures" for PTCL-NOS and DLBCL. Several highly overexpressed genes in both PTCL-NOS and DLBCL involve the immune network, stroma, angiogenesis, and cell survival cascades that make important contributions to lymphomagenesis. Inflammatory chemokines and their receptors likely play a central role in these complex interrelated pathways: CCL2 and CXCR4 in PTCL-NOS and CCL5 and CCR1 in DLBCL. Highly overexpressed oncogenes unique to PTCL-NOS are SPI1, STK6, α-PDGFR, and SH2D1A, whereas in DLBCL they are PIM1, PIM2, LYN, BCL2A1, and RAB13. Oncogenes common to both lymphomas are MAFB, MET, NF-κB2, LCK, and LYN. Several tumor suppressors are also down-regulated (TPTE, MGC154, PTCH, ST5, and SUI1). This study illustrates the relevance of tumor-stroma immune trafficking and identified potential novel prognostic markers and targets for therapeutic intervention.

UR - http://www.scopus.com/inward/record.url?scp=30344470789&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=30344470789&partnerID=8YFLogxK

U2 - 10.1158/1535-7163.MCT-05-0146

DO - 10.1158/1535-7163.MCT-05-0146

M3 - Article

C2 - 16373702

AN - SCOPUS:30344470789

VL - 4

SP - 1867

EP - 1879

JO - Molecular Cancer Therapeutics

JF - Molecular Cancer Therapeutics

SN - 1535-7163

IS - 12

ER -